The weight-loss shots people keep asking about
Two large trials show much more weight loss than placebo, and a lot of nausea. The shot is a prescribed medicine, not something an article can start for you.
Checked against the sources ยท Updated 17 Nov 2026
In short
- In large placebo-controlled trials, weekly semaglutide and weekly tirzepatide produced larger weight loss than placebo in adults with overweight or obesity and no diabetes. They are prescription medicines, with frequent gut side effects.
- STEP 1 and SURMOUNT-1, both large randomized trials, found double-digit average weight loss against placebo. Each medicine has one trial, paid for by its maker, and the Method keeps Clear evidence for several good studies that agree.
The weight-loss shots people keep asking about
Someone waits until the rest of the table is talking about something else, then asks you quietly whether those shots work. They have seen the before-and-after posts. They want a yes or a no they can carry home. The honest answer is narrower than the posts, and it is still a real answer.
In adults with overweight or obesity who did not have diabetes, once-weekly semaglutide and once-weekly tirzepatide each produced much more weight loss than placebo, in one large trial apiece. They are prescription medicines. Gut side effects were common. Nothing here sells them, ranks them, or hands out a dose. A clinician decides whether a person even fits the kind of adult who was studied.
Semaglutide, in one trial
STEP 1, published in 2021 in the New England Journal of Medicine, assigned 1,961 adults to semaglutide or placebo for 68 weeks. Both groups also followed a lifestyle program. People could enter with overweight or obesity, and diabetes was an exclusion.
Mean weight change was 14.9% down with semaglutide and 2.4% down with placebo. Those are averages from a large group. They are not a promise that any one person will land on the same percent.
Nausea was the most common gut event, 44.2% on semaglutide versus 17.4% on placebo. People left the semaglutide regimen because of gut events at 4.5%, versus 0.8% on placebo. The paper describes those events as mostly mild or moderate, and temporary. Common is still common. A medicine that often upsets the stomach is a different conversation from a supplement trend.
Gallbladder and pancreas events were uncommon, and they were more frequent on semaglutide. Counting events of any severity, gallbladder-related disorders, mostly gallstones, came to 2.6% versus 1.2%. Acute pancreatitis that the trial's own committee confirmed occurred in 3 people on semaglutide and in none on placebo. The paper describes those three cases as mild. One person had had pancreatitis before. The other two also had gallstones. All three recovered during the trial. These are counts from one trial, not a personal risk you can read off a post.
A public listing of the same trial posts serious events separately from the wider count. Those serious-event rows are a smaller set, not a second verdict on the same people. STEP 1 was funded by Novo Nordisk, which makes semaglutide. Who paid is part of reading the trial. It does not invent the weight change, and it does not erase the gut effects. It is a reason to want the result repeated by people who do not make the medicine. There is one trial here for this medicine, not several.
Tirzepatide, in a different trial
SURMOUNT-1, published in 2022 in the same journal, assigned 2,539 adults without diabetes to one of three weekly tirzepatide doses or to placebo for 72 weeks, including a stretch while the dose was going up. Diabetes was excluded. People could enter with obesity, or with overweight plus a related complication.
Mean weight change was 15.0%, 19.5%, and 20.9% down at the three doses, and 3.1% down on placebo. The most common side effects on tirzepatide were gastrointestinal, mostly mild or moderate, and they came mainly while the dose was rising. Some people stopped because of side effects, and that happened more often on the medicine than on placebo. SURMOUNT-1 was supported by Eli Lilly, which makes tirzepatide. Same note as above: one company-funded trial, a large one, with a gut-side-effect bill that showed up while the dose was climbing.
No dose is named for you to use. The three weekly amounts stay inside the paper. Quoting the percents is not an invitation to pick the largest one.
What the two trials cannot do for each other
These were not the same trial, so one percent is not a ranking over the other. They were not compared head to head. Both excluded diabetes. Both used a weekly injection under a study plan. Neither paper was a decision about registration in the Philippines, so nothing here says the products are registered and nothing here says they are unregistered.
Muscle changes during semaglutide belong to the other article, from a scan subset. They are a clinical topic, not a joke, and that article's numbers are not repeated here.
If the question at the table is whether the trials show weight loss, the answer is yes, against placebo, in one large company-funded trial for each medicine, with gut side effects that were common. One trial for each medicine is a real result. It is not several studies that agree. If the question is whether to start, that answer is not in an article.
Nothing here is for sale. A rating is not a queue, and an article is not a prescription.
What to take to a clinician, and then stop
- Take the trial percents, and ask whether you fit the kind of person who was studied. Adults with overweight or obesity, without diabetes, inside a study plan. If that is not you, the percent is not yours to borrow.
- Ask what the gut effects were, and what watching your strength would look like. The nausea figures above belong to the trial. They are not a script for adjusting anything yourself.
- Do not leave with a dose. An article cannot start the medicine. The person who can is a clinician, and only if it belongs in your care at all.
The quiet question deserves a straight answer. It does not deserve a shopping list.
When to be seen the same day
If you are already using one of these medicines and you cannot eat or drink, you are dizzy, or you have severe abdominal pain, that is a same-day clinical question. Do not wait to see whether a percent in a trial makes the symptom ordinary. The trials say gut events were often mild or moderate. They also say some people stopped, and that gallbladder and pancreas events, though uncommon, were more frequent on semaglutide. Severe pain, or not being able to keep food or drink down, is a reason to be seen. Bring the fact of the medicine with you.
---
Sources
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021. https://doi.org/10.1056/NEJMoa2032183
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022. https://doi.org/10.1056/NEJMoa2206038
- STEP 1 (NCT03548935): results and adverse events posted on ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03548935?tab=results
General guidance, not medical advice or a diagnosis. Talk with your doctor about your own health.
How strong is the evidence?
What the research says: In STEP 1, 86.4% versus 31.5% lost at least 5%. Nausea was 44.2% versus 17.4%, gastrointestinal disorders 74.2% versus 47.9%, and 4.5% versus 0.8% stopped for gastrointestinal events. The paper's adverse-event table gives gallbladder-related disorders at 2.6% versus 1.2%, gallstones (cholelithiasis) at 1.8% versus 0.6%, and adjudicated acute pancreatitis in 3 people versus 0. In SURMOUNT-1, 85%, 89%, and 91% across the three doses lost at least 5%, versus 35% on placebo.
What it doesn't say: This does not say which medicine is better, because they were not compared with each other. It does not give a dose to use. It does not say the products are registered, or unregistered, in the Philippines. Muscle loss is the subject of the previous article, not a reason for a joke here. Nothing on this page is for sale.
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
How we rate: the Flamel MethodTry this
- If you are curious, take the trial percents to a clinician and ask whether you even fit the kind of person who was studied. Curiosity is not an indication.
- Ask what the gut effects were in the trial, and what watching your strength would look like. Then stop. An article cannot start the medicine.
That counts.
See a doctor if You are already using one of these medicines and you cannot eat or drink, you are dizzy, or you have severe abdominal pain. That is a same-day clinical question.
Get delightful living tips directly in your email
Join freeKeep reading
Sources
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
- STEP 1 (NCT03548935): results and adverse events posted on ClinicalTrials.gov.
Last reviewed by Flamel Staff on 17 Nov 2026
Flamel is not medical advice and does not diagnose. If you have symptoms or readings in the red zone, see a doctor.